Related Experiment Video
Updated: Nov 15, 2025
08:04
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
12.2K
Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation:
Heidar J Albandar1, Jacob Fuqua2, Jasim M Albandar3
1West Virginia University Cancer Institute, Morgantown, WV 26506, USA.
Cancers
|March 6, 2021
Summary
Immune checkpoint inhibitor (ICI) therapy can cause immune-related adverse events (irAEs). This study found no significant survival difference in cancer patients who restarted ICI after irAEs compared to those who did not.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Treatment
Background:
- Immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) are increasingly recognized.
- Limited data exists on managing irAEs, particularly regarding treatment rechallenge.
- Understanding irAE management is crucial for optimizing cancer therapy outcomes.
Purpose of the Study:
- To investigate the impact of treatment rechallenge after irAEs in adult cancer patients receiving ICI therapy.
- To analyze survival outcomes based on whether ICI therapy was reinitiated after irAEs.
Main Methods:
- Retrospective analysis of adult cancer patients treated with ICI at WVU Cancer Institute (2011-2019).
- Reviewed 548 patients, identifying 133 with irAEs.
- Compared survival between patients who were rechallenged with ICI after irAEs and those whose treatment was discontinued.
Main Results:
- Anti-CTLA-4 inhibitor ICI was associated with a lower risk of death compared to anti-PD-1 ICI.
- Patients rechallenged with ICI after irAEs showed a trend towards better survival (37.8-38.6 months) than those not rechallenged (24.9 months), though not statistically significant.
- Demographics were similar between groups within cancer types.
Conclusions:
- Exploratory study in Appalachian West Virginia adult cancer patients.
- No statistically significant difference in survival was found between ICI rechallenged and non-rechallenged groups after irAEs.
- Further research is needed to establish definitive guidelines for ICI rechallenge post-irAEs.
Related Concept Videos
01:27Tumor Immunotherapy
850
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
850
01:21Cancer Survival Analysis
522
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
522